Joaquín Mosquera-Martínez

Dr. Joaquín Mosquera-Martínez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Clinical Lung Cancer
Verified
Journal Article
Closed access
JRJordi Remon
Jordi Remon
NGNicolas Girard
Nicolas Girard
SNSilvia Novello
Silvia Novello
JCJavier de Castro
Javier de Castro
LBLaurence Bigay-Game
Laurence Bigay-Game
BBBenjamin Besse
Benjamin Besse

20 October 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MMMarta Molina-Alejandre
Marta Molina-Alejandre
FPFrancisco Perea
Francisco Perea
VCVirginia Calvo
Virginia Calvo
CMCristina Martinez-Toledo
Cristina Martinez-Toledo
Ernest NadalErnest Nadal
Ernest Nadal
ACAlberto Cruz-Bermúdez
Alberto Cruz-Bermúdez
Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on perioperative chemoimmunotherapy (ChIO) efficacy or response mechanisms in the context of HLA class I defects. Methods Baseline HLA class I tumor status (HLA-deficient (HLA-DEF) or HLA-proficient (HLA-PRO)) was determined by DNA LOH combined with immunohistochemistry for protein levels in tissue of 24 patients with NSCLC treated with perioperative nivolumab plus chemotherapy from NADIM trial (NCT03081689). We integrated HLA tumor status with molecular data (programmed death-ligand 1 (PD-L1), TMB, TCR repertoire, TILs populations, bulk RNA-seq, and spatial transcriptomics (ST)) and clinical outcomes (pathological response and survival data) to study the activity of perioperative ChIO considering HLA class I defects. Results HLA-DEF tumors comprised 41.7% of analyzed tumors and showed a desert-like microenvironment at baseline, with lower PD-L1 levels and reduced immune infiltrate. However, perioperative ChIO induced similar complete pathological response (CPR) rates in both HLA-DEF and PRO tumors (50% and 60% respectively, p=0.670), as well as 3-year survival rates: Progression-free survival (PFS) and overall survival (OS) of 70% (95% CI 32.9% to 89.2%) for HLA-DEF, and PFS 71.4% (95% CI 40.6% to 88.2%) and OS 92.9% (95% CI 59.1% to 99.0%) for HLA-PRO (log-rank PFS p=0.909, OS p=0.137). Proof-of-concept ST analysis of a CPR HLA-DEF tumor after ChIO showed a strong immune response with tertiary lymphoid structures (TLS), CD4+T cells with HLA class II colocalization, and activated CD8+T cells. Conclusions Our findings highlight the activity of perioperative ChIO, and the potential role of TLS and T-cell immune response, in NSCLC HLA-DEF tumors.

26 February 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PFPaula Jimenez Fonseca
Paula Jimenez Fonseca
EGEnrique Gallardo
Enrique Gallardo
FAFernando Arranz Arija
Fernando Arranz Arija
JBJesús Manuel Blanco
Jesús Manuel Blanco
ACAna Callejo
Ana Callejo
ACAlberto Carmona-Bayonas
Alberto Carmona-Bayonas

13 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SMSilvia Masini
Silvia Masini
MAMónica Antoñanzas
Mónica Antoñanzas
ACAntonio Calles
Antonio Calles
RARuth Alvarrz Alvarez
Ruth Alvarrz Alvarez
IEIBONE DE ELEJOSTE ECHEBARRIA
IBONE DE ELEJOSTE ECHEBARRIA
JEJavier Baena Espinar
Javier Baena Espinar
Background/Objectives: Anti–PD-1/PD-L1 blockers have revolutionized the treatment landscape of non–small cell lung cancer (NSCLC) lacking oncogene-addicted alterations, particularly in tumors with high PD-L1 expression (tumor proportion score [TPS] ≥ 50%). Cemiplimab is approved as first-line monotherapy in this setting. However, real-world data remain scarce. This study aimed to evaluate the efficacy and safety of single-agent cemiplimab in a multicenter Spanish cohort and compare outcomes with a historical pembrolizumab cohort. Methods: Cemi-SPA is a retrospective multicenter study including 150 patients with advanced NSCLC and PD-L1 ≥ 50% treated with cemiplimab as first-line monotherapy across 21 Spanish centers. Clinical outcomes were analyzed and compared with a historical cohort of 144 patients treated with pembrolizumab. Propensity score matching (PSM) was performed to adjust for baseline differences. Results: Median progression-free survival (PFS) and overall survival (OS) were 8.1 and 12.6 months, respectively. ECOG performance status ≥ 2 was independently associated with worse outcomes, whereas the development of immune-related adverse events correlated with improved PFS and OS. After PSM, no significant differences were observed between cemiplimab and pembrolizumab in terms of efficacy. Conclusions: Cemiplimab demonstrated comparable real-world efficacy and safety to pembrolizumab in patients with advanced NSCLC and PD-L1 ≥ 50%. ECOG performance status emerged as the strongest prognostic factor, highlighting the importance of patient selection in routine clinical practice.

1 October 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
VCVirginia Calvo
Virginia Calvo
ECEnric Carcereny
Enric Carcereny
DAD. Rodriguez Abreu
D. Rodriguez Abreu
RCRafael López Castro
Rafael López Castro
MGMaría Guirado
María Guirado
Mariano ProvencioMariano Provencio
Mariano Provencio